Uncovering potential downstream targets of oncogenic GRPR overexpression in prostate carcinomas harboring ETS rearrangements

Oncoscience

Volumn 2, Issue 5, 2015, Pages 497-507

  Santos, Joana ^a   Mesquita, Diana ^a   Barros Silva, João D ^a   Jerónimo, Carmen ^a,b   Henrique, Rui ^a,b   Morais, António ^a   Paulo, Paula ^a   Teixeira, Manuel R ^a,b  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

ETS positive tumors; GRPR overexpression; Oncogenic role; Prostate cancer; Target genes

Indexed keywords

EID: 84958552285     PISSN: None     EISSN: 23314737     Source Type: Journal    
DOI: 10.18632/oncoscience.142     Document Type: Article

References (32)

1. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014; 64(1):9-29.
2. Ramon J and Denis L. Prostate Cancer. Springer, Berlim. 2007.
3. Feldman BJ and Feldman D. The development of androgen-independent prostate cancer. Nature reviews Cancer. 2001; 1(1):34-45.
4. Clark JP and Cooper CS. ETS gene fusions in prostate cancer. Nature reviews Urology. 2009; 6(8):429-439.
5. Kumar-Sinha C, Tomlins SA and Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nature reviews Cancer. 2008; 8(7):497-511.
6. Oikawa T and Yamada T. Molecular biology of the Ets family of transcription factors. Gene. 2003; 303:11-34.
7. Konstantinopoulos PA and Papavassiliou AG. Seeing the future of cancer-associated transcription factor drug targets. Jama. 2011; 305(22):2349-2350.
8. Findlay VJ, LaRue AC, Turner DP, Watson PM and Watson DK. Understanding the role of ETS-mediated gene regulation in complex biological processes. Advances in cancer research. 2013; 119:1-61.
9. Paulo P, Ribeiro FR, Santos J, Mesquita D, Almeida M, Barros-Silva JD, Itkonen H, Henrique R, Jeronimo C, Sveen A, Mills IG, Skotheim RI, Lothe RA, et al. Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements. Neoplasia. 2012; 14(7):600-611.
10. Xiao D, Wang J, Hampton LL and Weber HC. The human gastrin-releasing peptide receptor gene structure, its tissue expression and promoter. Gene. 2001; 264(1):95-103.
11. Cornelio DB, Roesler R and Schwartsmann G. Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2007; 18(9):1457-1466.
12. Markwalder R and Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer research. 1999; 59(5):1152-1159.
13. Hohla F and Schally AV. Targeting gastrin releasing peptide receptors: New options for the therapy and diagnosis of cancer. Cell cycle. 2010; 9(9):1738-1741.
14. Stangelberger A, Schally AV, Varga JL, Zarandi M, Szepeshazi K, Armatis P and Halmos G. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice. Clinical cancer research: an official journal of the American Association for Cancer Research. 2005; 11(1):49-57.
15. Stangelberger A, Schally AV, Varga JL, Hammann BD, Groot K, Halmos G, Cai RZ and Zarandi M. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers. The Prostate. 2005; 64(3):303-315.
16. Stangelberger A, Schally AV, Varga JL, Zarandi M, Cai RZ, Baker B, Hammann BD, Armatis P and Kanashiro CA. Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signalling. European journal of cancer. 2005; 41(17):2735-2744.
17. Jensen RT, Battey JF, Spindel ER and Benya RV. International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacological reviews. 2008; 60(1):1-42.
18. Mansi R, Fleischmann A, Macke HR and Reubi JC. Targeting GRPR in urological cancers--from basic research to clinical application. Nature reviews Urology. 2013; 10(4):235-244.
19. Morgan TM, Koreckij TD and Corey E. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Current cancer drug targets. 2009; 9(2):237-249.
20. Liu X, Carlisle DL, Swick MC, Gaither-Davis A, Grandis JR and Siegfried JM. Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib. Experimental cell research. 2007; 313(7):1361-1372.
21. Basu A and Sivaprasad U. Protein kinase Cepsilon makes the life and death decision. Cellular signalling. 2007; 19(8):1633-1642.
22. Gorin MA and Pan Q. Protein kinase C epsilon: an oncogene and emerging tumor biomarker. Molecular cancer. 2009; 8:9.
23. Zhang J, Baines CP, Zong C, Cardwell EM, Wang G, Vondriska TM and Ping P. Functional proteomic analysis of a three-tier PKCepsilon-Akt-eNOS signaling module in cardiac protection. American journal of physiology Heart and circulatory physiology. 2005; 288(2):H954-961.
24. Zong Y, Xin L, Goldstein AS, Lawson DA, Teitell MA and Witte ON. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(30):12465-12470.
25. Ubel C, Mousset S, Trufa D, Sirbu H and Finotto S. Establishing the role of tyrosine kinase 2 in cancer. Oncoimmunology. 2013; 2(1):e22840.
26. Ide H, Nakagawa T, Terado Y, Kamiyama Y, Muto S and Horie S. Tyk2 expression and its signaling enhances the invasiveness of prostate cancer cells. Biochemical and biophysical research communications. 2008; 369(2):292-296.
27. Schuster C, Muller M, Freissmuth M, Sexl V and Stoiber D. Commentary on H. Ide et al., "Tyk2 expression and its signaling enhances the invasiveness of prostate cancer cells". Biochemical and biophysical research communications. 2008; 366(4):869-870.
28. Yao HP, Zhou YQ, Zhang R and Wang MH. MSP-RON signalling in cancer: pathogenesis and therapeutic potential. Nature reviews Cancer. 2013; 13(7):466-481.
29. Mesquita D, Barros-Silva JD, Santos J, Skotheim R, Lothe RA, Paulo P and Teixeira MR. Specific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contexts. Oncotarget. (in press)
30. Paulo P, Barros-Silva JD, Ribeiro FR, Ramalho-Carvalho J, Jeronimo C, Henrique R, Lind GE, Skotheim RI, Lothe RA and Teixeira MR. FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer. Genes, chromosomes&cancer. 2012; 51(3):240-249.
31. Schmittgen TD and Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nature protocols. 2008; 3(6):1101-1108.
32. Cheadle C, Vawter MP, Freed WJ and Becker KG. Analysis of microarray data using Z score transformation. The Journal of molecular diagnostics: JMD. 2003; 5(2):73-81.